ASH 2024 – Piers Patten
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationPiers Patten discusses the potential of next-generation BCL-2 inhibitors like sonrotoclax compared to venetoclax in the treatment of CLL and shares insights on factors predictive of early MRD responses to BTK/BCL-2 inhibition in patients with CLL. He also provides an overview of the current understanding of the tumor microenvironment’s role in follicular lymphoma, highlighting key findings presented at ASH.